The National Cancer Institute (NCI) of the Department of Health and Human Services has issued a Notice of Funding Opportunity (NOFO) encouraging revision applications for the clinical validation of biomarker assays developed under existing NIH-supported research projects. The purpose is to accelerate the translation of molecular, cellular, and imaging markers for cancer detection, diagnosis, prognosis, and treatment response into clinical settings. Applicants are required to have assays with near-completed analytical validation and a focus on using human specimens. The funding opportunity emphasizes multidisciplinary collaboration among researchers, clinicians, and statisticians, with a budget limit of $150,000 per year over a maximum period of three years. Applications must adhere to specific guidelines, with submission deadlines beginning January 14, 2025, and concluding on October 15, 2026. This NOFO aims to facilitate the advancement of biomarker assays, which, despite their promising development stages, often struggle to achieve clinical utility due to inadequate validation processes. The initiative reflects a strategic approach of the NIH to bridge the gap between research and practical clinical applications for cancer patients.